BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
PR Newswire —
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax (Ascentage Pharma), Sonrotoclax (BeOne Medicines), LP-118 and LP-108 (Newave Pharmaceutical),...